Monash University researchers have found in laboratory experiments that a drug that delivers copper to the brain significantly reduces toxic Alzheimer’s proteins and improves long-term spatial memory.
There are few treatment options available for people with disorders of the esophagus. Delivering drugs directly to this part of the body is difficult, so patients are usually treated with systemic drugs, which can have unwanted side effects.
Following infection, the Ebola virus can survive unnoticed in the human body for months or even years, hiding in areas with little immune surveillance like the central nervous system.
Researchers from NYU Abu Dhabi, in collaboration with Cleveland Clinic Abu Dhabi, have developed a tiny, injectable medical device that introduces a new approach to treating chronic pain and movement disorders by controlling nerve activity without the need for surgery, batteries or wires, offering a simpler and less invasive way to treat neurological conditions.
To utilize flexible bioelectronic systems for wound healing, researchers designed the MSWZ. The MSWZ is made up of a mechanical metamaterial in a lattice structure that shrinks and responds like human skin, a reliable conductive layer, and a breathable, flexible encapsulation material.
For patients suffering from traumatic injuries that leave behind “volumetric” gaps—where significant bone and blood vessels are lost—the clock is always ticking. Without a nearby blood supply, cells in the center of a large injury cannot survive, often leading to permanent tissue loss or failed grafts.
Glucosamine use is associated with a 25% higher odds that a person will progress from mild cognitive impairment to dementia and Alzheimer’s disease, researchers report in the journal Nature Metabolism.
Biohub and UC Berkeley show that the laser phase plate, a revolutionary device with a laser 100 million times brighter than the Sun, dramatically improves images obtained through cryo-electron microscopy, giving scientists a new window into the molecular underpinnings of disease
People with mild cognitive impairment (MCI) are at higher risk of developing dementia. Indeed, many of them experience a gradual decline in cognitive performance over time. Smartphone- or tablet-based memory tests can capture this subtle decline more quickly than conventional testing. These findings come from a study by DZNE in collaboration with university hospitals in Germany, the University of Wisconsin–Madison in the United States, and the startup neotiv.
The integration of AI into digital pathology has the potential to transform cancer diagnostics by enabling scalable, quantitative analysis of tissue specimens. However, widespread deployment of AI-assisted pathology remains challenged by the need for costly imaging infrastructure and the lack of reliable mechanisms to assess prediction confidence.